Evidências - Kantar Health highlights budget impact for cancer treatment at ISPOR Europe Congress 2018

Evidências - Kantar Health highlights budget impact for cancer treatment at ISPOR Europe Congress 2018

Evidências - Kantar Health will participate in the 21st annual European Congress of the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) with two posters. The event will be held in Barcelona, Spain from November 10th to 14th and is one of the most important scientific dissemination channels on pharmacoeconomics and outcomes research. At the conference will be presented posters of the works carried out by Evidências - Kantar Health in the last semester addressing innovative subjects.

The first poster named Budget impact model of subcutaneous rituximab compared with intravenous rituximab in the treatment of CD-20 positive non-Hodgkin lymphoma in the Brazilian private healthcare system aimed to estimate the cost of using subcutaneous rituximab compared to intravenous for the treatment of CD-20 positive non-Hodgkin's lymphoma (NHL). The research obtained direct medical costs and prices from public sources. Also, the poster was elected as one of the semifinalists of the Research Poster Presentation Award at ISPOR Europe 2018 in Barcelona.

The second study titled Budget impact model of subcutaneous trastuzumab compared with intravenous trastuzumab on the treatment of HER-2 positive breast cancer in the Brazilian Private Healthcare System estimated the budget impact of the drug in the Private Healthcare System for the treatment of initial and metastatic HER-2 positive breast cancer. The initial breast cancer treatments were trastuzumab monotherapy and trastuzumab with paclitaxel or docetaxel. In metastatic breast cancer, trastuzumab was associated with docetaxel or paclitaxel in the first line and monotherapy in the second. For both, it was compared the replacement of intravenous trastuzumab by the subcutaneous.

ISPOR

ISPOR is one of the most important scientific channels for dissemination of pharmacoeconomics and outcomes research. Besides being a public non-profit organization for educational and scientific purposes, the objective of ISPOR is promoting the science of pharmacoeconomics and the research results and facilitating the translation of this research into useful information for decision makers in the area of healthcare. The society has more than 6,500 members in 100 countries and 62 regional chapters with over 4,800 members. ISPOR promotes three annual meetings, conducted in North America, Europe, and Latin America or Asia.

Check in the PDF below the Evidências - Kantar Health’s presentations at ISPOR Europe 2018.

Search
Newsletter

Subscribe to our newsletter

More